Exciting Collaboration: Orbis Medicines and Vivtex Team Up for Innovative Drug Development
Partnership Announcement Between Orbis Medicines and Vivtex
In a groundbreaking collaboration, Orbis Medicines has joined forces with Vivtex to innovate the realm of oral biologic therapies. Orbis, celebrated for its advancements in oral macrocycle drug discovery, aims to leverage Vivtex’s cutting-edge GI-ORIS™ platform. This partnership is designed to enhance the screening process for gut permeability and optimize the oral bioavailability of ***nCycles***, Orbis's latest macrocycle drug innovations.
The Vision Behind the Collaboration
"This collaboration expands our capabilities to design for oral bioavailability during the critical preclinical development stages. The resources offered by Vivtex’s validated ex vivo porcine gut model greatly aid in understanding human gut interactions," noted Simon Feldbæk, Managing Director and Chief Development Officer at Orbis. This strategic partnership aims to fast-track the development of top-quality drug candidates poised for clinical testing.
Focus on the nCycles Platform
With the agreement in place, both companies will conduct extensive permeability screenings of Orbis' ***nCycles***. These innovative macrocycles are systematically designed using Orbis’s proprietary “nGen” platform, targeting the long-standing issues of oral bioavailability and membrane permeability. The aim is to deliver effective oral alternatives for numerous blockbuster biologics.
Vivtex’s Role in Advancing Drug Delivery
Vivtex's renowned GI-ORIS™ platform plays a pivotal role in this collaboration. It allows researchers to automate the screening process in a way that captures the complexity of the gastrointestinal tract while testing vast numbers of samples within a single day. This technology has the potential to significantly reduce the time and resources typically required for such experiments, accelerating the development timeline for new therapies.
Understanding Orbis Medicines
Orbis Medicines is at the forefront of a transformative approach to oral macrocycle drug discovery. The ability of macrocycles to possess desirable therapeutic properties, combined with the capabilities of the ***nGen*** platform, positions the company to explore vast chemical spaces while delivering viable drug candidates. Orbis is actively focused on creating high-value oral alternatives to existing biologic therapies, a mission that aligns with its founding by Novo Holdings.
Insights into the nGen Platform
The ***nGen*** platform is a revolutionary tool for generating oral macrocycle candidates, also termed ***nCycles***. Utilizing a massive library of over 100 billion compounds, Orbis integrates advanced automation and machine learning to quickly progress candidate drugs. The data generated through this innovative method not only accelerates the development process but also enhances the quality of the candidates selected for further study.
The Vision of Vivtex Corporation
Vivtex, established by researchers from prestigious institutions, is committed to reimagining the way biologic therapies are developed. By focusing on the transformation of injectable biologics into oral versions, Vivtex aims to broaden therapeutic access to patients who may benefit from these treatments. Emphasizing the importance of its proprietary GI-ORIS™ platform, Vivtex is determined to provide reliable solutions for delivering effective oral biologics.
Advancing Biologic Therapies
With a vision to revolutionize the market for biologic therapies, Vivtex is pioneering the development of oral biologics that could significantly enhance patient compliance and treatment effectiveness. Their established relationships with various biotechnology and pharmaceutical firms further bolster their innovative approach, emphasizing collaboration as key to advancing therapeutic research.
Frequently Asked Questions
What is the main goal of the Orbis and Vivtex collaboration?
The main goal is to enhance the development of oral biologic therapies using Vivtex’s GI-ORIS™ platform for gut permeability screening, optimizing the bioavailability of Orbis’ ***nCycles***.
What are ***nCycles***?
***nCycles*** are next-generation macrocycle drug candidates being developed by Orbis Medicines, designed to be orally bioavailable and membrane permeable, addressing historical challenges in drug design.
How does the GI-ORIS™ platform work?
The GI-ORIS™ platform automates the screening process, capturing the GI tract's complexity in a microwell plate format, allowing for rapid testing of thousands of drug samples.
What therapeutic areas does Orbis target?
Orbis targets high-value oral alternatives to established biologics, aiming to offer effective treatments for numerous medical conditions that currently require injectable therapies.
Who founded Orbis Medicines?
Orbis Medicines was founded by Novo Holdings, reflecting its commitment to pioneering advancements in oral macrocycle drug discovery.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- NaturalShrimp, Inc. Navigates Challenges with Resilience and Growth
- Legal Action Announced for Endava PLC DAVA Stock Investors
- West Michigan's Renewable Energy Commitment Sets a New Standard
- Strategic Alliance between Kimray and Kathairos in Emission Control
- Transforming Legal Accounting: Virtual Assistants from Legal Soft
- Artificial Superintelligence Alliance Sees Strong Price Gains
- Sivers Semiconductors Proposes Share Issue and Employee Options
- Exciting Northern Tool + Equipment Collaboration with Monster Jam
- Affordable and Exciting 2024 Holiday Toy Picks You Need
- Platinum Equity and Butterfly Strategically Acquire Rise Baking
Recent Articles
- Fortress Transportation Achieves New Heights with Stock Surge
- Dutch Stocks Surge as AEX Reaches New Heights Today
- Tarana's ngFWA Technology Transforms Broadband Access in U.S.
- AIM ImmunoTech's CEO Takes Notable Step in Company Investment
- DigitSec Integrates with Salesforce Security Center for Enhanced Protection
- Portugal Stock Market Shows Positive Movement with PSI Gains
- Spanish Markets Surge as IBEX 35 Reaches New Heights
- Innovative Security Solutions from Obsidian and CrowdStrike
- Kingfisher PLC Leads the Charge as U.K. Stocks Gain Ground
- Navitas Semiconductor's Stock Response to Leadership Change
- Meal Ticket Partners with Pepper for Enhanced Ordering Solutions
- Google Rethinks Santiago Data Center Amid Environmental Issues
- Mid Atlantic Radiology Consultants Partners with HAP for Success
- BlackRock's iShares Bitcoin Trust Gains Momentum with Inflow
- Marathon Digital CEO Weighs in on MicroStrategy's Latest Move
- Revolutionizing IT: VergeIO's Innovative Migration Training Labs
- Rose Rocket Unveils Software Partnership for Southern Markets
- Koch Ag & Energy Solutions Partners with Cognite for Digital Evolution
- Nexilico and Siolta Therapeutics Pursue Revolutionary NEC Treatment
- Rottendorf Pharma Enhances Validation with ValGenesis VLMS Solution
- ServiceTitan Joins Forces with Authority Brands for Growth
- Enhancing Payment Security: Bluefin Partners with Moneris
- JetBlue and Cape Air Strengthen Loyalty Program for Travelers
- Tivic Health Partners with FSI to Enhance Vagus Nerve Therapy
- Collaborative Efforts for Clean Hydrogen Solutions Through Ammonia
- Transform Your $100 Investment into $900: Insights on MARA
- Exciting Partnership to Propel Robotics Technology Forward
- Amazon's Stock Surge: Insights on Recent Developments
- Enventure Global Technology Secures Key Contract for Innovations
- Empowering Teens with Free AI Bootcamp in Detroit
- Nagomi Security Joins Forces with CrowdStrike for Enhanced Protection
- Important Class Action Updates for EXTR, PDD, CXM, and SYM Investors
- Butler Transit Authority Launches Innovative RideBTA System
- Boosting AI Skills: Free Bootcamp for Teens Offered Here
- Innovative Electric-Powered Trailer System by Range Energy
- UK Fortifies Its Defenses Against Mpox Variants with New Vaccines
- Breakthrough Partnership in Cancer Treatment: PharmaJet and Scancell
- Class Action Lawsuit Filed Against ZoomInfo Technologies for Investors
- Innovative Partnership Between Consensus Cloud Solutions and Olah
- Unforgettable Electrify Expo Experience in Seattle Showcases EV Innovation
- Deepwatch Revolutionizes Cybersecurity with Innovative Platform Modules
- Empowering Teens Through Free AI Bootcamp in Houston
- United Language Group Secures $1.8M Grant for Health Initiatives
- Elastic Expands Reach Through Partnership with Arrow Electronics
- GTT Reports Share Buyback Activities: Detailed Overview
- Transforming Active Shooter Response with Secure Grid Innovation
- Arzeda Closes Successful Funding Round to Propel Protein Innovations
- Empowering Teens: Free AI Bootcamp Offers Future Skills
- Empowering Minneapolis Youth Through Free AI Bootcamp Program
- Innovative Partnership for Renewable Energy from Almonds